Phenytoin blood concentrations in hospitalized geriatric patients: Oral versus nasogastric feeding tube administration

Therapeutic Drug Monitoring

Volumn 32, Issue 2, 2010, Pages 185-188

  Lubart, Emilia ^a   Berkovitch, Matitiahu ^b   Leibovitz, Arthur ^a   Orly, Dafni ^b   Segal, Refael ^a  

^a Tel Aviv University Sackler Faculty of Medicine   (Israel)

^b ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

Elderly; Pharmacokinetics; Phenytoin; Therapeutic drug monitoring

Indexed keywords

PHENYTOIN;

AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DYSPHAGIA; FEMALE; GERIATRIC PATIENT; HOSPITAL PATIENT; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NASOGASTRIC TUBE; NOSE FEEDING; PRIORITY JOURNAL; SEIZURE; AGE; BLOOD; DIGESTIVE TRACT INTUBATION; GERIATRICS; HOSPITALIZATION; ORAL DRUG ADMINISTRATION; PROCEDURES; VERY ELDERLY;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; GERIATRICS; HOSPITALIZATION; HUMANS; INTUBATION, GASTROINTESTINAL; MALE; PHENYTOIN;

EID: 77950277213     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181d3fa3e     Document Type: Article

References (28)

1. Gillic MR. Rethinking the role of tube feeding in patients with advanced dementia. N Engl J Med. 2000;342:206-310.
2. Ciocon JO. Indication for the tube feeding in elderly patients. Dysphagia. 1990;5:1-5.
3. Woolfson AM, Saour JN, Ricketts CR, et al. Prolonged nasogastric tube feeding in critically ill and surgical patients. Postgrad Med J. 1976;52: 678-682.
4. Weir RF, Gostin L. Decisions to abate life-sustaining treatment for nonautonomous patients. Ethical standards and legal liability for physicians after Cruzan. JAMA. 1990;264:1846-1853.
5. Solomon MZ, O'Donnell L, Jennings B, et al. Decisions near the end of life: professional views on life-sustaining treatments. Am J Public Health. 1993;83:14-23.
6. O'Brien LA, Sieger EA, Grisso JA, et al. Tube feeding preferences among nursing home residents. J Gen Intern Med. 1997;12:364-371.
7. Schneider JS, Ouellette SM. Sucralfate administration via nasogastric tube. N Engl J Med. 1984;310:990.
8. Larson C, Cavuto NJ, Flockhart DA, et al. Bioavailability and efficacy of omeprazole given orally and by nasogastric tube. Dig Dis Sci. 1996;41: 475-479.
9. Fish DN, Abraham E. Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patients. Antimicrob Agents Chemother. 1999;43:1277-1280.
10. Mimoz O, Binter V, Jacolot A, et al. Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. Intensive Care Med. 1998;24:1047-1051.
11. Kitchen D, Smith D. Problems with phenytoin administration in neurology/neurosurgery ITU patients receiving enteral feeding. Seizure. 2001;10:265-268.
12. Au Yeung SC, Ensom MH. Phenytoin and enteral feedings: does evidence support an interaction? Ann Pharmacother. 2000;34:896-905.
13. Williams NT. Medication administration through enteral feeding tubes. Am J Health Syst Pharmacol. 2008;65:2347-2357.
14. Dickerson RN. Medication administration considerations for patients receiving enteral tube feedings. Hosp Pharm. 2004;39:84-96.
15. Nyffeler MS, Frankel E, Hayes E, et al. Drug-nutrient interactions. In: Merritt R, DeLegge MH, Holcombe B, et al, eds. The ASPEN Nutrition Support Practice Manual. 2nd ed. Silver Spring, MD: American Society for Parenteral and Enteral Nutrition; 2005:118-136.
16. Belknap DC, Seifert CF, Petermann M. Administration of medication through enteral feeding catheters. Am J Crit Care. 1997;6:382-392.
17. Gilbert S, Hatton J, Magnuson B. How to minimize interaction between phenytoin and enteral feedings: two approaches. Nutr Clin Pract. 1996; 11:28-31.
18. Krueger KA, Garnett WR, Comstock TJ, et al. Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability. Epilepsia. 1987;28:706-712.
19. Marvel ME, Bertino JS. Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension. JPEN J Parenter Enteral Nutr. 1991;15:316-319.
20. Doak KK, Curtis EH, Dunnigan KJ, et al. Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings. Pharmacotherapy. 1998;18:637-645.
21. Nishimura LY, Armstrong EP, Plezia PM, et al. Influence of enteral feeding on phenytoin sodium absorption from capsules. Drug Intell Clin Pharm. 1988;22:130-133.
22. Bauer LA. Interference of oral phenytoin absorption by continuous naso-gastric feeding. Neurology. 1982;32:570-572.
23. Faraji B, Yu PP. Serum phenytoin level of patients on gastrostomy tube. J Neurosci Nurs. 1998;30:55-59.
24. Ozuna J, Friel P. Effect of enteral tube feeding on serum phenytoin levels. J Neurosurg Nurs. 1984;16:289-291.
25. Bader MK. Case study of two methods for enteral phenytoin administration. J Neurosci Nurs. 1993;25:233-242.
26. O'Hagan M, Wallace SJ. Enteral formula feeds interfere with phenytoin absorption. Brain Dev. 1994;16:165-167.
27. Cutie AJ, Altman E, Lenkel L. Compatibility of enteral products with commonly employed drug additives. JPEN J Parenter Enteral Nutr. 1983; 7:186-191.
28. Fleisher D, Sheth N, Kou JH. Phenytoin interaction with enteral feedings administered through nasogastric tubes. JPEN J Parenter Enteral Nutr. 1990;14:513-516.